ASCO 2024 | Integration of PSMA-PET into routine clinical practice for patients with prostate cancer

Wolfgang Fendler • 1 Jun 2024

ASCO 2024

Wolfgang Fendler, MD, University Hospital Essen, Essen, Germany, discusses the integration of PSMA-PET into routine clinical practice for prostate cancer staging and prognosis. PSMA-PET is already one of the key imaging modalities at initial, recurrent, and metastatic stages of prostate cancer. In the future, PSMA-PET could also be used in these settings to separate patients into low-risk and high-risk groups and help clinicians choose the right therapy accordingly. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Honoraria – Parexel
Consulting or Advisory Role – Calyx; Janssen
Speakers’ Bureau – ABX Advanced biochemical compounds; Amgen; Bayer; Eczacibasi Monrol; GE Healthcare; Janssen; Novartis; Telix Pharmaceuticals
Research Funding – SOFIE